For estrogen receptor- (ER-) or progesterone receptor- (PR-) positive breast cancers, hormone-based treatment, such as ovarian ablation, tamoxifen, or aromatase inhibitors, has been demonstrated to result in an improvement in disease-free survival (DFS) and overall survival (OS) [1, 2]. This evidence concerns the gene PGR and breast carcinoma.